Compare CRI & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRI | QURE |
|---|---|---|
| Founded | 1865 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2002 | 2013 |
| Metric | CRI | QURE |
|---|---|---|
| Price | $39.57 | $25.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 14 |
| Target Price | $35.60 | ★ $45.00 |
| AVG Volume (30 Days) | 1.1M | ★ 2.0M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $2,898,426,000.00 | $13,107,000.00 |
| Revenue This Year | $4.57 | $126.12 |
| Revenue Next Year | $1.12 | $200.43 |
| P/E Ratio | $98.05 | ★ N/A |
| Revenue Growth | ★ 1.91 | N/A |
| 52 Week Low | $23.38 | $8.73 |
| 52 Week High | $44.44 | $71.50 |
| Indicator | CRI | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 63.81 | 59.18 |
| Support Level | $32.05 | $22.59 |
| Resistance Level | $41.09 | $25.66 |
| Average True Range (ATR) | 1.72 | 2.09 |
| MACD | 0.56 | -0.35 |
| Stochastic Oscillator | 82.81 | 35.08 |
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.